Evidence map›Paper›PMID 39655913›Full record

ArticleAntimicrobial agents and chemotherapy2025

Cefiderocol pharmacokinetics during acute pulmonary exacerbations in hospitalized adult persons with cystic fibrosis.

Christina Koenig, Marguerite L Monogue, Ryan K Shields, Colleen M Sakon, Andrew J Fratoni, Hanna F Roenfanz, James D Finklea, James S Pope, David P Nicolau, Joseph L Kuti

Abstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Christina KoenigCenter for Anti-Infective Research & Development, Hartford Hospital, Hartford, Connecticut, USA.ORCID 0000-0002-3354-3496
Marguerite L MonogueThe University of Texas Southwestern Medical Center, Dallas, Texas, USA.ORCID 0000-0001-8251-458X
Ryan K ShieldsUniversity of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.ORCID 0000-0001-9794-5665
Colleen M SakonIndiana University Health, Indianapolis, Indiana, USA.
Andrew J FratoniCenter for Anti-Infective Research & Development, Hartford Hospital, Hartford, Connecticut, USA.
Hanna F RoenfanzCenter for Anti-Infective Research & Development, Hartford Hospital, Hartford, Connecticut, USA.
James D FinkleaThe University of Texas Southwestern Medical Center, Dallas, Texas, USA.
James S PopeDivision of Pulmonary and Critical Care Medicine, Hartford Hospital, Hartford, Connecticut, USA.
David P NicolauCenter for Anti-Infective Research & Development, Hartford Hospital, Hartford, Connecticut, USA.ORCID 0000-0002-4148-0165
Joseph L KutiCenter for Anti-Infective Research & Development, Hartford Hospital, Hartford, Connecticut, USA.ORCID 0000-0002-4464-3126

Funding

Shionogi (Shionogi & Co. Ltd.) Investigator Initiated Grant
6 · The paper itself

Abstract

Persons with CF (pwCF) present altered pharmacokinetics (PK) and are often infected with multidrug-resistant (MDR) bacteria. Herein, we describe the PK of cefiderocol, a siderophore cephalosporin with potent activity against MDR Gram-negative rods, in hospitalized adult pwCF with acute pulmonary exacerbation (APE). PwCF received ≥3 doses of 2 g cefiderocol (3 h infusion) with frequency determined according to their estimated glomerular filtration rate (eGFR). Blood sampling collected at steady state. Concentrations were fitted using the non-parametric adaptive grid algorithm in Pmetrics for R. Ten pwCF were enrolled; nine completed the study with six receiving 2 g q8 h and three 2 g q6 h. A two-compartment model best fitted the data. Mean (SD) PK parameters were clearance, 5.66 (1.28) L/h; volume of central compartment, 5.81 (3.52) L, and intercompartment transfer constants, k12, 4.29 (3.46) and k21, 2.25 (2.76) h

Indexed as

Anti-Bacterial AgentsCephalosporinsCystic FibrosisAdultCefiderocolFemaleGlomerular Filtration RateHospitalizationHumansMaleMicrobial Sensitivity TestsMiddle AgedYoung AdultAnti-Bacterial AgentsCefiderocolCephalosporinsbeta-lactamcefiderocolcystic fibrosispharmacokinetics

Identifiers

PMID39655913
PMCPMC11784235

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.